As part of the Agios deal Servier also took rights to vorasidenib – a dual inhibitor of mutated IDH1 and IDH2 – that is in trials for a hard-to-treat form of brain cancer called glioma.

This leaflet answers some common questions about DIAMICRON 60 mg MR. It does not contain all the available information Reading this leaflet does not take the place of talking to your doctor ...

Servier is extending its pact with Google Cloud as the French biopharma points to 60 examples of how generative artificial intelligence could improve its drug development processes. The two ...